ApprovedFDA approval

Zenbexus (iberdomide)

Bristol Myers Squibb (BMY)

Marketer take

An oral CELMoD used with daratumumab-based therapy after one prior line including a PI and IMiD, so it targets community oncologists' early-relapse sequencing decisions rather than the late-line centers where CAR-T competes.

Sponsor company
Bristol Myers Squibb (BMY)
Indication
To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
Therapeutic area
Oncology, Hematology
Event
FDA approval
Date
Aug 13, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move